Symbicort is expensive primarily because it has been protected by patents that prevented generic competition in the United States for nearly two decades, and because it’s a complex inhaler device rather than a simple pill. The average retail price for a 90-day supply runs around $415 in the U.S., while the same medication costs roughly 65% less through international pharmacies. Several factors stack on top of each other to keep that price high, though recent changes are finally starting to bring costs down.
Patents Blocked Competition for Years
AstraZeneca’s original Symbicort was approved by the FDA in 2006. The company holds patents on the U.S. version that don’t fully expire until somewhere between 2025 and 2029, including extensions granted for pediatric studies. That’s over two decades of market protection for a single inhaler. In contrast, Symbicort’s patents have already expired in the EU, Japan, and China, where cheaper alternatives have been available for longer.
The first generic, called Breyna, was approved by the FDA in 2022 and is made by Viatris (formerly Mylan). But approval and widespread availability are two different things. Patients have reported paying anywhere from $5 to $89 per month for the generic depending on their insurance, pharmacy, and timing. Some have gotten it through mail-order pharmacy for as little as $22 for a 90-day supply. The inconsistency in generic pricing reflects how new the product still is in the market and how much insurance plan design affects what you actually pay.
Inhalers Are Harder to Copy Than Pills
A generic version of a tablet just needs to contain the same active ingredient in the same amount. Inhalers are far more complicated. Symbicort is a pressurized metered-dose inhaler that must deliver a precise amount of medication deep into the lungs with every puff. The device, the propellant, the particle size, and the valve mechanism all have to work together consistently. The FDA treats generic inhalers more like new medical devices than simple copies, requiring extensive testing to prove they perform identically to the original. This higher regulatory bar means fewer companies attempt to make generic inhalers, and those that do spend years and significant money getting approval. Less competition means higher prices.
The Rebate System Inflates List Prices
The sticker price you see at the pharmacy counter doesn’t reflect what insurers and pharmacy benefit managers (PBMs) actually pay. Before 2024, confidential rebates on brand-name inhalers ran between 50% and 70% off the list price. In practice, this means AstraZeneca was setting a high list price knowing that a large chunk would be rebated back to insurers and PBMs behind the scenes. The problem is that patients without insurance, or those with high-deductible plans, get stuck paying based on that inflated list price rather than the lower negotiated price.
This rebate dynamic also creates a perverse incentive. A brand-name inhaler with a $300 list price and a 60% rebate costs the insurer $120, which can be close to or even lower than the list price of a generic. That makes it harder for generics to gain traction, because insurers sometimes prefer the brand they’re getting deep discounts on. A 2025 analysis in Health Affairs found that when brand-name inhaler list prices dropped in 2024, generic uptake actually increased, suggesting the old high-price-plus-rebate model had been suppressing generic competition.
Other Countries Pay Far Less
The price gap between the U.S. and the rest of the world is stark. A single Symbicort inhaler with 120 doses can be found internationally for around $155, compared to roughly $415 for a 90-day supply in the U.S. Countries with single-payer health systems negotiate drug prices directly with manufacturers, giving them far more bargaining power than individual American insurers have. The U.S. has historically had no mechanism for the government to negotiate prices on most drugs, which is one reason the same product costs dramatically more here.
New Policies Are Starting to Lower Costs
Two recent developments are shifting the landscape. First, the Inflation Reduction Act of 2022 gave Medicare the authority to negotiate prices on certain high-cost drugs for the first time. The first round of negotiated prices was announced in August 2024 and takes effect in 2026. While Symbicort wasn’t in the initial batch of ten drugs selected, the program is designed to expand over time, targeting medications that cost Medicare the most.
Second, AstraZeneca voluntarily capped out-of-pocket costs at $35 per month for its entire inhaler lineup starting June 1, 2024. This applies to Symbicort along with several other respiratory medications. The cap covers uninsured and underinsured patients, which addresses the group most harmed by high list prices. There’s a significant catch, though: people enrolled in federal insurance programs like Medicare or Medicaid are excluded from the co-pay savings program due to government restrictions.
How to Pay Less Right Now
If you’re paying full price for Symbicort, you have several options. The most straightforward is asking your pharmacy or doctor about switching to the generic, Breyna. Patient experiences vary widely, but many report paying between $5 and $30 per month, especially through mail-order pharmacies. Some patients have noticed differences in taste or feel between Breyna and brand-name Symbicort, but the FDA requires the generic to deliver the same medication at the same dose.
AstraZeneca runs two assistance programs. The co-pay savings program helps commercially insured patients, and the AZ&Me program provides medication at no cost to qualifying uninsured and Medicare patients. Enrollment lasts up to one year and can be renewed. Medications are mailed directly to your home or your doctor’s office, and there’s no fee to sign up.
If you have commercial insurance, the $35 monthly cap applies automatically through AstraZeneca’s savings program. For those on high-deductible plans where the inhaler hits before your deductible is met, using a manufacturer coupon or switching to generic can cut costs dramatically. The days of routinely paying $200 or more per month for this medication are ending, but navigating the options still requires asking your pharmacist what’s actually cheapest under your specific plan.